Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Gilead

Gilead Sciences' Q2 2024 Earnings: What to Expect

Gilead Sciences is expected to release its fiscal second-quarter earnings next month, and analysts project a double-digit profit increase.

Is Gilead Sciences Stock Underperforming the Nasdaq?

Is Gilead Sciences Stock Underperforming the Nasdaq?

Gilead Sciences has recently underperformed the broader Nasdaq Composite, but analysts are reasonably bullish about the stock’s outlook.

3 Dividend Growth Stocks to Buy and Hold

3 Dividend Growth Stocks to Buy and Hold

These three dividend-paying growth stocks are worth a look at current levels as the odds rise for Fed rate cuts.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Pharma Firm Urged To Share New 'Game-changer' HIV Drug

More than 300 politicians, health experts and celebrities on Thursday called for US pharmaceutical giant Gilead to allow cheap, generic versions of a promising new HIV drug to be produced so it can reach people in developing countries most affected by the deadly disease.

International Business Times

Gilead Sciences Stock Outlook: Is Wall Street Bullish or Bearish?

Gilead Sciences has underperformed the broader market YTD, but Wall Street analysts are still cautiously optimistic about the stock’s prospects.

Stocks Plunge Before the Open as Meta’s Revenue Forecast Disappoints, U.S. GDP Data and Earnings in Focus

June S&P 500 E-Mini futures (ESM24) are down -0.53%, and June Nasdaq 100 E-Mini futures (NQM24) are down -0.87% this morning as a disappointing revenue outlook for the current quarter from Meta weighed on sentiment, while market participants braced for a new round of U.S. economic data and quarterly reports…

Lawsuits Against Gilead Sciences Could Stifle Medical Innovation

Lawsuit against Gilead Sciences raises concerns about innovation impact in drug development and potential implications on future product development.

inkl

Read news from The Economist, FT, and more,
with one subscription

Is Gilead Sciences Stock a Buy Near 52-Week Lows for Its 4% Yield?

Is Gilead Sciences Stock a Buy Near 52-Week Lows for Its 4% Yield?

Gilead Sciences stock has trailed the broader markets by a significant margin over the last eight years. Is this high-yield dividend stock a good buy right now?

Gilead (GILD) Quarterly Earnings: Buy or Sell Signal?

Gilead (GILD) Quarterly Earnings: Buy or Sell Signal?

Biotech major Gilead Sciences (GILD) will release its fourth-quarter results on February 6. The company is expected to report growth in earnings over the prior-year quarter, but its revenue is expected to decline. Given the expected decline in its revenue, how should investors play this stock? Read on to learn…

Gilead Sciences (GILD) Earnings Forecast and Gameplan

Gilead Sciences (GILD) boasts an impressive product portfolio and has surpassed the consensus estimate on the topline in each of the trailing four quarters. With the company gearing up to post its third quarter results, is GILD a wise investment now? Read on.

Using Market Volatility to Your Advantage: Selling a GILD Put Option Before Earnings

Using Market Volatility to Your Advantage: Selling a GILD Put Option Before Earnings

A trader selling the November 10th, $76-strike put on GILD would receive around $105 into their account, which would be theirs to keep.

How to Enhance Your Own Strategies with POWR Ratings

How to Enhance Your Own Strategies with POWR Ratings

Wall Street is never lacking in strategy or trading ideas. In investing, if you can combine two or more strategies that align around a particular investing idea, you can enhance your likelihood of success. This idea combines our POWR Ratings with a strategy that is currently making the rounds on…

Top 3 Biotech Stocks Leading the Way This October

Top 3 Biotech Stocks Leading the Way This October

The biotech industry is well-positioned for strong growth thanks to increasing demand for high-quality treatments for chronic diseases. Given this backdrop, quality biotech stocks Jazz Pharmaceuticals (JAZZ), Amgen (AMGN), and Gilead Sciences (GILD) could be solid buys for October. Read on….

3 Best Biotech Stocks for Growth in 2023

3 Best Biotech Stocks for Growth in 2023

The biotech industry is well-positioned for solid growth due to the growing demand for high-quality treatments for chronic diseases and an aging population. Therefore, it could be wise to invest in fundamentally strong biotech stocks Jazz Pharmaceuticals (JAZZ), Alkermes (ALKS), and Gilead Sciences (GILD), given their solid growth prospects. Read…

Get all your
news in one place.

100's of premium titles.
One news app.

Big Pharma’s playbook for expensive meds

Here are just a few of the many examples of drug pricing practices that have driven consumers to demand change

Major brands are pulling ads on Musk's X after posts appeared beside pro-Nazi content

"If trust is lost it's like a house of cards—and currently X lacks trust from both its audiences and its B2B partners."

Buy, Hold or Sell? Gilead Sciences Inc. (GILD) and Moderna Inc. (MRNA)

Rapid breakthroughs and surging demand position the biotech sector for significant expansion in the near term. Therefore, quality biotech stock Gilead Sciences (GILD) could be worth buying. However, I think it will be best to wait for a better entry point in Moderna (MRNA). Read on.

3 of the Best Stocks in 1 of Wall Street's Worst-Rated Industry

After years of robust growth, the biotech industry has struggled since last year due to several headwinds, including regulatory concerns, inflation, and the Fed’s aggressive rate hikes, which have sucked out speculative capital. Despite currently being one of the poorly-rated industries, investors could consider buying top-biotech stocks Gilead (GILD), Vertex…

Get all your
news in one place.

100's of premium titles.
One news app.

2 Dividend Stocks That Could Pay You for the Rest of Your Life

As the market remains volatile due to ongoing concerns about elevated inflation, prolonged rate hikes, and an impending recession, fundamentally strong dividend stocks Bristol-Myers Squibb (BMY) Gilead Sciences (GILD) might be ideal buys to ensure a stable income stream. Moreover, these stocks could be great long-term investments. Read more.

1 Resilient Growth Stock to Buy Now and Hold Forever

Biopharmaceutical giant Gilead Sciences’ (GILD) shares have risen nearly 30% over the past year despite lingering macroeconomic challenges. Moreover, the company delivered solid growth last year and is expected to maintain its business momentum in 2023 and beyond, driven by its diversified medicines portfolio. Hence, investors could consider buying and…

At buzzy health care business conference, investors fear the bubble will burst

JPMorgan's cheery confab returned to San Francisco, but the health care capitalists had economic anxiety, too.

Health care investors convene in SF

Health care’s business class returned to San Francisco last week for JPMorgan’s annual health care confab

Want Passive Income in a Bear Market? Check out This Biotech Stock

With the minutes of the latest Fed meeting showing that interest rates will keep increasing this year, the economy is widely expected to enter a recession. Amid the expected downturn this year, it could be wise to buy biotech stock Gilead Sciences (GILD) due to its solid growth prospects and…

2 Biotech Stocks to Buy Amid a Blazing Hot Run

A rapidly aging population and the rise in lifestyle diseases drive the biotech industry’s growth. Through their cutting-edge research, biotech companies are coming up with new solutions to develop treatments. Given the solid long-term prospects of the industry, it could be wise to buy fundamentally strong biotech stocks Amgen Inc.…

Up More than 19% In 2022, Is Gilead Sciences Still a Buy?

Gilead Sciences (GILD) beat revenue and earnings estimates in the previous quarter and upgraded its guidance for fiscal 2022. Having risen more than 19% year-to-date, is GILD still a buy? Read on to learn our view.

1 … 5 6 7 8

People

Kritika SarmahHer

Dipanjan BanchurSince

Mangeet Kaur BounsMangeet

Steve Reitmeister

Linda Yaccarino

Steven AdamsAfter

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

US Federal Reserve

Intel Corporation

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Developing Countries

Places

405,666 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play